In:
Diabetes Care, American Diabetes Association, Vol. 32, No. 1 ( 2009-01-01), p. 126-128
Abstract:
OBJECTIVE—To investigate renal elimination of the adipokine fibroblast growth factor 21 (FGF21) by determining circulating FGF21 levels in patients on chronic hemodialysis (CD) as compared with control subjects with a glomerular filtration rate (GFR) & gt;50 ml/min. RESEARCH DESIGN AND METHODS—FGF21 was determined by enzyme-linked immunosorbent assay in control (n = 60) and CD (n = 60) patients and correlated to clinical and biochemical measures of renal function, glucose and lipid metabolism, and inflammation in both groups. RESULTS—Median serum FGF21 levels were & gt;15-fold higher in CD patients (3,710.6 ng/l) than in subjects with a GFR & gt;50 ml/min (201.9 ng/l) (P & lt; 0.001). Furthermore, serum creatinine positively and GFR negatively predicted FGF21 concentrations in multiple regression analyses in control subjects (P & lt; 0.05). CONCLUSIONS—FGF21 serum levels increase in CD patients and are related to markers of renal function in control subjects.
Type of Medium:
Online Resource
ISSN:
0149-5992
,
1935-5548
Language:
English
Publisher:
American Diabetes Association
Publication Date:
2009
detail.hit.zdb_id:
1490520-6
Permalink
